Loading...
XLONHCM
Market cap165mUSD
Dec 24, Last price  
242.00GBP
1D
-3.38%
1Q
-11.24%
Jan 2017
0.88%
IPO
838.52%
Name

HUTCHMED (China) Ltd

Chart & Performance

D1W1MN
XLON:HCM chart
P/E
524.62
P/S
63.09
EPS
0.58
Div Yield, %
0.00%
Shrs. gr., 5y
-23.52%
Rev. gr., 5y
31.38%
Revenues
838m
+96.52%
37,860,36250,433,25065,109,71186,971,422110,996,951134,509,287166,924,326195,392,00045,970,00091,813,000178,203,000216,080,000241,203,000214,109,000204,890,000227,976,000356,128,000426,409,000837,999,000
Net income
101m
P
000000710,2233,638,0005,915,0005,374,0007,993,00011,698,000-26,737,000-74,805,000-144,379,000-194,563,000-227,658,000-410,139,000100,780,000
CFO
219m
P
000011,627,12705,201,57215,661,0005,028,00013,360,000-9,385,000-9,569,000-8,943,000-32,847,000-80,912,000-62,066,000-204,223,000-268,599,000219,258,000
Earnings
Feb 26, 2025

Profile

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.
IPO date
May 19, 2006
Employees
1,990
Domiciled in
HK
Incorporated in
KY

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
837,999
96.52%
426,409
19.73%
356,128
56.21%
Cost of revenue
820,678
714,796
592,806
Unusual Expense (Income)
NOPBT
17,321
(288,387)
(236,678)
NOPBT Margin
2.07%
Operating Taxes
4,509
(283)
11,918
Tax Rate
26.03%
NOPAT
12,812
(288,104)
(248,596)
Net income
100,780
-124.57%
(410,139)
80.16%
(227,658)
17.01%
Dividends
(87,436)
(99,744)
Dividend yield
10.47%
5.38%
Proceeds from repurchase of equity
(3,977)
(47,910)
660,501
BB yield
1.89%
5.74%
-35.63%
Debt
Debt current
35,082
264,621
26,905
Long-term debt
57,836
28,496
14,322
Deferred revenue
69,480
190
878
Other long-term liabilities
11,346
12,472
10,685
Net debt
(841,829)
(93,938)
(412,794)
Cash flow
Cash from operating activities
219,258
(268,599)
(204,223)
CAPEX
(32,612)
(36,664)
(16,756)
Cash from investing activities
(291,136)
296,588
(306,320)
Cash from financing activities
48,660
(82,763)
650,028
FCF
210,687
(524,048)
(269,612)
Balance
Cash
886,336
630,996
1,011,700
Long term investments
48,411
(243,941)
(557,679)
Excess cash
892,847
365,735
436,215
Stockholders' equity
(770,897)
(858,500)
(465,682)
Invested Capital
1,681,241
1,794,841
1,535,279
ROIC
0.74%
ROCE
1.90%
EV
Common stock shares outstanding
173,839
847,144
792,685
Price
1.21
22.53%
0.99
-57.87%
2.34
9.56%
Market cap
209,882
-74.86%
834,719
-54.97%
1,853,825
24.43%
EV
(619,101)
769,187
1,493,652
EBITDA
25,528
(279,723)
(229,488)
EV/EBITDA
Interest
759
652
592
Interest/NOPBT
4.38%